All Pfizer articles – Page 2
-
BusinessEncouraging signs from initial Covid-19 vaccine trials
Human trials deliver positive immune responses, while primate challenge studies suggest protection is possible
-
BusinessPfizer’s Upjohn to merge with Mylan
Deal combines Pfizer’s off-patent drug portfolio with Mylan’s generics
-
ResearchBaran and Blackmond team up to wave farewell to tough ether syntheses
Oxidative decarboxylation produces carbocations that greatly speed up hindered ether production
-
BusinessPfizer to close two manufacturing plants in India
Closures will lead to the loss of 1700 jobs – almost 6% of the pharma giant’s manufacturing workforce
-
BusinessGSK and Pfizer joint venture creates new consumer healthcare giant
Enlarged GSK consumer health will have largest market share of any firm and be a leader in key countries
-
OpinionPushing the limits of patent protection
Some methods of extending exclusivity rights raise legal and ethical questions
-
OpinionThe projects drug companies wish they’d never started
Failures are common in drug research, but some are bigger than others
-
BusinessTrump coaxes big promises from big pharma
Several drug industry giants are now pledging to freeze price increases in the US, but some suggest the movement is a publicity stunt or worse
-
NewsEnglish health service could recover £500m in drug costs from Pfizer
NHS England may have paid over the odds for pain drug whose patent has now been revoked
-
Research1500 reactions per day go with the flow
Automated flow chemistry system puts high-speed spin on drug discovery
-
BusinessDementia slips down pharma agenda
Pfizer, Shire, Acorda and Axovant rethink their neuroscience strategies
-
-
BusinessUS to invest $160m in cancer partnership
Funds will be backed up with $55m from 11 companies to advance new cancer treatments that harness the immune system
-
BusinessLong road to recovery for Puerto Rico pharmaceuticals
As inhabitants begin to rebuild their lives after the devastation of hurricane Maria, the island’s drug manufacturers are recovering slowly
-
BusinessAmgen partners to launch biosimilars in China
US biopharma and Chinese generics firm will co-develop medicines from Amgen’s pipeline focused on inflammation and oncology
-
BusinessFDA warns Pfizer subsidiary over Epipen malfunctions
Manufacturer did not fully investigate reports of patients dying after auto-injector failures
-
-
BusinessUS court denies Amgen appeal over Pfizer biosimilar
Amgen has lost its bid to compel Pfizer to divulge information about its version of anaemia drug Epogen
-
BusinessAmplifying intelligent drug design
This year’s Chemistry World Entrepreneur of the year is Andrew Hopkins of start-up Exscientia and the University of Dundee, UK
-
BusinessFirst biomarker-driven approval exemplifies cancer immunotherapy progress
Landmark decision is latest step in field’s impressive – but not wholly untroubled – advance